Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Insulet Corp
(NQ:
PODD
)
202.77
-2.38 (-1.16%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Insulet Corp
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Insulet Highlights New Data For Omnipod 5 System For Type 1, Type 2 Diabetes
April 27, 2022
Insulet Corporation (NASDAQ: PODD) unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes patients. Paired with...
Via
Benzinga
Insulet Presents New Omnipod® 5 System Data for Type 1 and Type 2 Diabetes
April 27, 2022
From
Insulet Corporation
Via
Business Wire
Insulet to Announce First Quarter 2022 Financial Results on May 5, 2022
April 07, 2022
From
Insulet Corporation
Via
Business Wire
Insulet Posts Street-Beating Q4 Earnings, Omnipod Revenues Up ~20%
February 24, 2022
Insulet Corp's (NASDAQ: PODD) Q4 FY21 revenue increased 25% (25.7% in constant currency) to $307.7 million, exceeding the consensus of $301.06 million. The company...
Via
Benzinga
Expert Ratings For Insulet
January 31, 2022
Analysts have provided the following ratings for Insulet (NASDAQ:PODD) within the last quarter:
Via
Benzinga
Recap: Insulet Q4 Earnings
February 23, 2022
Insulet (NASDAQ:PODD) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Insulet...
Via
Benzinga
Insulet Reports Full Year 2021 Revenue Increase of 21% and Fourth Quarter 2021 Revenue Increase of 25% Year-Over-Year
February 23, 2022
From
Insulet Corporation
Via
Business Wire
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
February 23, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...
Via
Benzinga
Insulet to Present at Upcoming Investor Conferences
February 16, 2022
From
Insulet Corporation
Via
Business Wire
Earnings Scheduled For February 23, 2022
February 23, 2022
Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM)...
Via
Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Via
Benzinga
Insulet Announces Board Appointment of Elizabeth Weatherman and Retirement of David Lemoine
February 07, 2022
From
Insulet Corporation
Via
Business Wire
Insulet Promotes Inclusivity for People with Diabetes through Nintendo® Video Game Animal Crossing™: New Horizons
February 17, 2022
From
Insulet Corporation
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2022
February 03, 2022
Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ:PODD) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022
February 02, 2022
Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
January 28, 2022
Gainers Provention Bio (NASDAQ:PRVB) stoc...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022
January 31, 2022
Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago...
Via
Benzinga
FDA Approves Insulet's Omnipod Automated Insulin Delivery System Patients Aged 6 Years & Above
January 28, 2022
The
Via
Benzinga
52 Biggest Movers From Friday
January 31, 2022
Gainers Knightscope, Inc. (NASDAQ: KSCP) surged 175.6% to close at $3.40 on Friday. The company, on Thursday, priced its IPO at $10 per share. Imperial Petroleum Inc. (NASDAQ:...
Via
Benzinga
Mid-Day Market Update: US Stocks Turn Positive; Nasdaq Surges 2%
January 28, 2022
US stocks turned higher, with all the three major indices recording gains. The Nasdaq climbed more than 2% following stronger-than-expected earnings results from Apple Inc. (...
Via
Benzinga
33 Stocks Moving In Friday's Mid-Day Session
January 28, 2022
Gainers Imperial Petroleum Inc. (NASDAQ: IMPP) shares jumped 126% to $2.6219. Imperial Petroleum, last month, posted Q3 revenue of $4.1 million. Yoshitsu Co., Ltd (NASDAQ: TKLF...
Via
Benzinga
Benzinga Pro's Top 5 Stocks To Watch For Friday, Jan. 28, 2022: PODD, KR, TEAM, GOOGL, SBUX
January 28, 2022
Today's 5 Stock Ideas: Insulet (PODD) - Shares up premarket. The company announced FDA clearance of its Omnipod 5 Automated Insulin Delivery System. Kroger (KR) - Shares...
Via
Benzinga
Insulet Announces FDA Clearance of its Omnipod® 5 Automated Insulin Delivery System, First Tubeless System with Smartphone Control
January 28, 2022
From
Insulet Corporation
Via
Business Wire
If You Invested $100 In This Stock 5 Years Ago, Here's How Much You Would Have Today
January 13, 2022
Insulet (NASDAQ:PODD) has outperformed the market over the past 5 years by 24.86% on an annualized basis. Buying $100 In PODD: 5 years ago, an investor could have purchased 2.30...
Via
Benzinga
This Foreboding Sign Looms Over Insulet's Chart
January 13, 2022
If history is any guide, there may be trouble ahead for shares of Insulet (NASDAQ:PODD). A so-called "death cross" has formed on its chart and, not surprisingly, this could be...
Via
Benzinga
CORRECTING and REPLACING Insulet to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
January 12, 2022
From
Insulet Corporation
Via
Business Wire
Insulet to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2021
January 12, 2022
From
Insulet Corporation
Via
Business Wire
Insulet to Present at Nasdaq’s 45th Investor Conference
November 24, 2021
From
Insulet Corporation
Via
Business Wire
10 Biggest Price Target Changes For Monday
November 08, 2021
Barclays cut Deciphera Pharmaceuticals, Inc. (NASDAQ:
Via
Benzinga
10 Biggest Price Target Changes For Friday
November 05, 2021
Wedbush raised Uber Technologies, Inc. (NYSE:UBER)...
Via
Benzinga
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.